Dune gets FDA panel nod for breast cancer detector

Maryland's Dune Medical Devices won a 10-1 vote from an FDA advisory panel on MarginProbe, the company's breast cancer surgery aid. The device is designed to minimize the need for repeat operations after breast-conservation surgeries by detecting the presence of cancer at or near the surface of excised tissue. In a trial of 600 patients, Dune found that MarginProbe significantly reduced the rate of follow-up surgeries, the company said. The device is already available in Europe, and, after filing a PMA with the FDA in 2011, the company expects to get MarginProbe on U.S. shelves soon. Release | More

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.